GlassScriptPhysician profile
Nami L Cho
NPI 1023091683
$1,949.15
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $517 · 2020: $88.06 · 2021: $49.83 · 2022: $495 · 2023: $593 · 2024: $206.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $799.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $799.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $449.46 | 2019-2024 | Ubrelvy |
| Glaxosmithkline, LLC. | $346.87 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $272.57 | 2019-2024 | Ozempic, Rybelsus |
| Amarin Pharma, INC. | $242.48 | 2019-2022 | |
| Abbott Laboratories | $166.84 | 2021-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $61.45 | 2019-2023 | Xifaxan, Trulance |
| Astrazeneca Pharmaceuticals LP | $51.49 | 2019-2022 | |
| Lilly USA, LLC | $43.44 | 2023-2024 | Mounjaro, Jardiance |
| Amgen INC. | $31.72 | 2023-2024 | Prolia, Evenity, Repatha |
| Pfizer INC. | $30.69 | 2020 | |
| Allergan, INC. | $29.45 | 2019 | |
| Novartis Pharmaceuticals Corporation | $28.63 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $24.21 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $21.30 | 2024 | Uptravi, Opsumit |
| Phathom Pharmaceuticals, INC. | $21.20 | 2024 | Voquezna |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $19.23 | 2019 | |
| Dexcom, INC. | $19.06 | 2023 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.43 | 2022 | |
| Janssen Pharmaceuticals, INC | $14.82 | 2019 | |
| Astellas Pharma US INC | $13.19 | 2022 | |
| Neos Therapeutics, LP | $12.86 | 2022 | |
| Sanofi-Aventis U.S. LLC | $11.35 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $11.08 | 2020 | |
| Organon LLC | $9.33 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nami Cho listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.